Prostate-specific membrane antigen (PSMA) is highly expressed by poorly differentiated, metastatic, and castration-resistant prostate cancer cells,1 creating a good imaging and therapeutic target. 177Lutetium (Lu) is a beta-emitting radionuclide that induces DNA strand breaks and cellular lethality.2 In the situation of 177Lu-PSMA-617, 177Lu is linked to a 617, which is a small molecule targeting vector that binds to PSMA. Once bound to the receptor on the target cell membrane, in this case, prostate cancer cell, the complex is internalized.3 Hence, the lethal radiopeptide is delivered internally to induce DNA breaks and eventual apoptosis.